About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease.

News

June 2, 2020
Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase

May 28, 2020
Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

May 26, 2020
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Events

June 5, 2020
BioNJ COVID-19 Rapid Fire Research Showcase

May 19, 2020
LSX Inv€$tival Showcase Digital

May 7, 2020
Caladrius Biosciences 1st Quarter 2020 Financial Results and Business Update Conference Call

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

CD34 Cell Technology